Data from several multicenter, long-term cardiovascular outcome trials (CVOTs) with GLP-1 RAs indicated cardiovascular benefit in patients with T2DM with CVD or at very high/high risk (Lixisenatide ELIXA [118], Liraglutide LEADER [119], Semaglutide SUSTAIN 6 [120], Exenatide EXSCEL [121], Albiglutide Harmony Outcomes [122], Dulaglutide REWIND [123], and Oral semaglutide PIONEER 6 [124]. Here, GCG is linked to type 2 diabetes mellitus.